

AMENDMENT &amp; RESPONSE UNDER 37 C.F.R. § 1.116

Serial Number: 09/512,926

Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALY-COMPROMISED VASCULAR SMOOTH MUSCLE

Page 2

Dkt: 875.039US1

Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application:

- Claim 1. (Currently amended) A method to normalize the contractile response of an endothelially-compromised vascular smooth muscle cell in response to a vasoconstrictor agonist in a patient in need of such normalization, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.
- Claims 2-5 (Cancelled)
- Claim 6. (Currently amended) A method of claim 23, ~~wherein the~~ wherein the compound administered is 1-p- $\beta$ -dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.
- Claim 7. (Previously presented) A method of claim 23, wherein the patient has diabetes.
- Claim 8. (Previously presented) A method of claim 23, wherein the patient has had a surgical procedure.
- Claim 9. (Previously presented) A method of claim 23, wherein the patient has hypertension.
- Claim 10. (Previously presented) A method of claim 23, wherein the patient has coronary artery disease.
- Claim 11. (Previously presented) A method of claim 23, which further comprises administering a pharmaceutically-effective compound selected from the group

Do not  
enter  
12/19/03

AMENDMENT &amp; RESPONSE UNDER 37 C.F.R. § 1.116

Serial Number: 09/512,926

Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALY-COMPROMISED VASCULAR SMOOTH MUSCLE


Page 3

Dkt: 875.039US1

consisting of: an anti-diabetes agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-restenosis agent.

Claims 12-22 (Cancelled)

Claim 23. (Previously presented) A method of claim 1, wherein the CLC3 blocker is a compound of Formula I



wherein

either  $R^4$  is H or a lower alkyl radical and  $R^5$  is a lower alkyl radical, or  $R^4$  and  $R^5$  are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

$R^6$  is H or a lower alkyl radical;

$R^7$  is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

$R^8$  is H or OH; and

$n$  is 2;

or a pharmaceutically acceptable salt thereof.

Claim 24. (Cancelled)

AMENDMENT &amp; RESPONSE UNDER 37 C.F.R. § 1.116

Serial Number: 09/512,926

Filing Date: February 25, 2000

Page 4

Dkt: 875.039US1

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIAALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

Claim 25. (New) A method to normalize the contractile response of an endothelially-compromised vascular smooth muscle cell in response to a vasoconstrictor agonist in a patient in need of such normalization, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof, wherein the vasoconstrictor agonist is norepinephrine, KCl or serotonin.